Decreased cell mediated cytotoxicity occurs frequently in inflammatory bowel disease, particularly in patients with active disease. It is not clear, however, whether this decrease is caused by the disease or is a consequence of the medical treatment. In this study we evaluated the effect of in vivo treatment with 5-aminosalicylic acid and sulphasalazine on the in vitro natural killer cell activity in five patients with inflammatory bowel disease in remission and in four healthy control subjects in a double blind randomised crossover trial preceded and separated by four weeks of treatment with placebo. The natural killer cell activity was significantly impaired in 67% (six of nine subjects) after four weeks' sulphasalazine treatment and tended to be related to subjects with a slow acetylator phenotype. In contrast, 5-aminosalicylic acid treatment caused only a marginal reaction in the natural killer cell activity in 22% (two of nine subjects). The inhibitory effects were found to be reversible since the decreased natural killer cell activity was completely restored after placebo treatment in all subjects. In conclusion, in vivo treatment with sulphasalazine inhibits the in vitro natural killer cell activity and this seems to be mediated by the sulphapyridine moiety. This phenomenon may contribute to the low natural killer cell activity found in patients with active inflammatory bowel disease. rheumatoid arthritis. Its mode of action is still unclear, although it has been shown to possess both antibacterial and immunosuppressive activity. The active moiety seems to be 5-aminosalicylic acid in inflammatory bowel disease and sulphapyridine in rheumatoid arthritis." The immunosuppressive activity of the drugs has been illustrated by inhibition of phagocyte chemotaxis, oxygen metabolite production, leukotriene production, and lymphocyte proliferative activity in vitro.'2"15 Moreover, sulphasalazine and sulphapyridine were recently shown to inhibit in vitro cellular cytotoxicity of both peripheral blood and intestinal mononuclear cells.'"'8 It is still unclear, whether in vivo treatment with sulphasalazine has a similar inhibitory effect on natural killer cell activity. Since deranged cell mediated cytotoxicity does not seem to be involved in the pathogenesis of inflammatory bowel disease,56 inhibition of natural killer cell activity by sulphasalazine may result in insufficient clearing of infected and malignant cells.
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Results
The natural killer cell activity was similar in patients and control subjects at the end of the placebo periods (Table I ). The mean cytotoxicity values of the two placebo periods were identical in patients and controls (combined 64-6 (5) v 68 5 (5 7)). Moreover, the reproducibility of the natural killer cell activity determinations, expressed as the correlation coefficient of the two placebo periods from patients and controls, was good (r=0-95, p<0 02).
The natural killer cell activity after the sulphasalazine period was significantly decreased both in patients and controls compared with the mean of the two preceding placebo periods (p<0O05, Table I ). In contrast, 5-aminosalicylic acid did not affect the natural killer cell activity in the control subjects and only marginally in the patients. The natural killer cell activity was impaired -that is, below the lowest placebo value (46-2%) -after sulphasalazine treatment in six (67%) subjects (three patients and three controls) (Fig (a) ), but was reduced in only two subjects (one patient and one control) after 5-aminosalicylic acid treatment (Fig (b) ). All patients remained in remission during the different treatment periods. Thus, the changes in the natural killer cell activity were not attributable to the disease activity according to the Harvey and Bradshaw index (Table II) . Neither the concentration of sulphasalazine nor of its metabolites in serum were found to be related to the change in natural killer cell activity or the resulting natural killer cell activity at the end of the sulphasalazine treatment period (Table III) . The percentage of subjects with an impaired natural killer cell activity after sulphasalazine treatment tended to be higher, however, in the slow acetylator group (80%, four of five) than in the fast acetylator group (50%, two of four).
Discussion
Treatment with sulphasalazine suppresses natural killer cell activity of peripheral blood cells in vitro, which seems to be more prominent in subjects with a slow acetylator phenotype. In * contrast, 5-aminosalicylic acid had no significant effect on natural killer cell activity. Studies on natural killer cells in inflammatory X.... bowel disease indicate that these cells probably 5-ASA do not play a role in the pathogenesis of the 
